IP Library › Granted Patent US 12,385,049
Granted Patent B2
US 12,385,049 · App. 18/049,593 · Granted Aug 12, 2025

Modification of RNA, producing an increased transcript stability and translation efficiency

Inventors: Ugur Sahin (Mainz, DE); Silke Holtkamp (Mainz, DE); Ozlem Tureci (Mainz, DE); Sebastian Kreiter (Mainz, DE)
Assignee: BioNTech SE
C12N15/68C12N15/67C12N15/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,385,049
App. No.
18/049,593
Granted
Aug 12, 2025
Kind
B2
Abstract

It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

Claims (70)

1. An immunogenic composition comprising:

an mRNA molecule comprising, in a 5′ to 3′ orientation:

(a) a 5′ cap,

(b) a sequence that encodes an antigen and ends with a termination codon,

(c) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,

wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;

wherein the 3′-UTR is heterologous with respect to the sequence that encodes the antigen.

2. The immunogenic composition of claim 1 , wherein upon delivery of the immunogenic composition into a mammalian cell, the stability and/or translation efficiency of the mRNA molecule is increased, as compared to that of an mRNA molecule without the 3′-terminal poly(A) tail sequence (c).

3. The immunogenic composition of claim 1 , wherein the 3′-terminal poly(A) tail sequence has a length of 100 consecutive A nucleotides.

4. The immunogenic composition of claim 1 , wherein the 3′-terminal poly(A) tail sequence has a length of 120 consecutive A nucleotides.

5. The immunogenic composition of claim 1 , wherein the 3′-UTR comprises a 3′ UTR of a globin gene.

6. The immunogenic composition of claim 1 , wherein the mRNA molecule comprises a non-natural nucleotide analog.

7. The immunogenic composition of claim 1 , wherein the antigen comprises a tumor antigen.

8. The immunogenic composition of claim 1 , wherein the mRNA molecule is an in vitro transcribed mRNA molecule.

9. The immunogenic composition of claim 1 , wherein the antigen comprises a peptide or protein.

10. An isolated mammalian cell comprising:

an mRNA molecule comprising, in a 5′ to 3′ orientation:

(a) a 5′ cap,

(b) a sequence that encodes a peptide or a protein and ends with a termination codon,

(c) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,

wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;

wherein the 3′-UTR is heterologous with respect to the sequence that encodes the peptide or the protein; and

wherein stability and/or translation efficiency of the mRNA molecule is increased as compared to that of an mRNA molecule with a poly(A) tail sequence that is shorter than 100 consecutive A nucleotides.

11. The isolated mammalian cell of claim 10 , wherein the 3′-terminal poly(A) tail sequence has a length of 100 consecutive A nucleotides.

12. The isolated mammalian cell of claim 10 , wherein the mRNA molecule comprises at least one of the following features:

a non-natural nucleotide analog; or

a 3′-UTR that comprises a 3′-UTR of a globin gene; and

a 3′UTR that comprises a ribosome binding sequence.

13. The isolated mammalian cell of claim 10 , wherein the mRNA molecule is an in vitro transcribed mRNA molecule.

14. The isolated mammalian cell of claim 10 , wherein the peptide or protein comprises an antigen.

15. The isolated mammalian cell of claim 10 , wherein the 3′-terminal poly(A) tail sequence has a length of 120 consecutive A nucleotides.

16. An isolated antigen-presenting cell comprising:

an mRNA molecule comprising, in a 5′ to 3′ orientation:

(b) a sequence that encodes a peptide or a protein and ends with a termination codon,

(c) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,

wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;

wherein the 3′-UTR is heterologous with respect to the sequence encoding the peptide or the protein.

17. The isolated antigen-presenting cell of claim 16 , wherein the antigen-presenting cell is a dendritic cell.

18. The isolated antigen-presenting cell of claim 16 , wherein the peptide or the protein comprises an antigen.

19. The isolated antigen-presenting cell of claim 16 , wherein the 3′-terminal poly(A) tail sequence has a length of 100 consecutive A nucleotides.

20. The isolated antigen-presenting cell of claim 16 , wherein the mRNA molecule comprises at least one of the following features:

a non-natural nucleotide analog; or

a 3′-UTR that comprises a 3′-UTR of a globin gene.

21. The isolated antigen-presenting cell of claim 16 , wherein the mRNA molecule is an in vitro transcribed mRNA molecule.

22. The isolated antigen-presenting cell of claim 16 , wherein stability and/or translation efficiency of the mRNA molecule is increased as compared to that of an mRNA molecule with a poly(A) tail sequence consisting of no more than 51 consecutive A nucleotides.

23. The isolated antigen-presenting cell of claim 16 , wherein the 3′-terminal poly(A) tail sequence has a length of 120 consecutive A nucleotides.

24. A method for stimulating or expanding antigen-specific T cells, the method comprising steps of:

(a) obtaining an mRNA molecule comprising, in a 5′ to 3′ orientation:

(i) a 5′ cap,

(ii) a sequence that encodes an antigen and ends with a termination codon,

(iii) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,

wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;

wherein the 3′-UTR is heterologous with respect to the sequence that encodes the antigen;

(b) delivering the mRNA molecule to antigen-presenting cells under conditions such that the encoded antigen is expressed in the antigen-presenting cells; and

(c) exposing T cells to the antigen-presenting cells from (b) under conditions that stimulate or expand antigen-specific T cells, wherein the number of antigen-specific T cells is increased, as compared to that of an mRNA molecule having a poly(A) tail sequence of no more than 51 consecutive A nucleotides.

25. The method of claim 24 , wherein the T cells comprise CD4 + and/or CD8 + T cells, and/or wherein the antigen-presenting cells are or comprise dendritic cells.

26. The method of claim 24 , wherein the mRNA molecule is delivered to the antigen-presenting cells by transfection in vitro.

27. The method of claim 24 , wherein stability and/or translation efficiency of the mRNA molecule is increased as compared to that of an mRNA molecule with a poly(A) tail sequence of 51 consecutive A nucleotides.

28. A method of producing in vitro an mRNA molecule suitable for use as a pharmaceutical, the method comprising steps of:

(i) obtaining a nucleic acid molecule comprising (a) a first nucleic acid sequence which codes for a nucleotide sequence comprising 100 to 150 consecutive A nucleotides, (b) a second nucleic acid sequence which is transcribable into mRNA, wherein the first nucleic acid sequence is located at the 3′ end of the second nucleic acid sequence, and (c) a recognition sequence for a type IIS restriction endonuclease that is located 3′ of the first nucleic acid sequence such that the corresponding cleavage site for the type IIS restriction endonuclease is located within the first nucleic acid sequence;

(ii) cleaving the first nucleic acid sequence of the nucleic acid molecule from step (i) with a type IIS restriction endonuclease; and

(iii) transcribing in vitro the nucleic acid molecule obtained after step (ii) thereby forming a transcript which comprises the mRNA transcribed from the second nucleic acid sequence and a 3-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides, wherein the 3-terminal nucleotide of said transcript is an A nucleotide, and

wherein the transcript formed from step (iii) is characterized in that upon delivery into a mammalian cell, the stability and/or translation efficiency of the transcript is increased, as compared to that of a transcript without the 3′-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides.

29. A method of increasing the stability of an in vitro-transcribed mRNA molecule, the method comprising steps of:

(i) obtaining a nucleic acid molecule comprising (a) a first nucleic acid sequence which, when transcribed, codes for a nucleotide sequence comprising 100 to 150 consecutive A nucleotides, (b) a second nucleic acid sequence which is transcribable into mRNA, wherein the first nucleic acid sequence is located at the 3′ end of the second nucleic acid sequence, and (c) a recognition sequence for a type IIS restriction endonuclease, that is located 3′ of the first nucleic acid sequence, such that the corresponding cleavage site for the type IIS restriction endonuclease is located within the first nucleic acid sequence;

(ii) cleaving the first nucleic acid sequence of the nucleic acid molecule from step (i) with a type IIS restriction endonuclease; and

(iii) transcribing in vitro the nucleic acid molecule obtained after step (ii) thereby forming a transcript which comprises the mRNA transcribed from the second nucleic acid sequence and a 3-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides, wherein the 3-terminal nucleotide of said transcript is an A nucleotide, wherein stability of the transcript is greater than that of a transcript without a 3′-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides.

30. A method of increasing the expression efficiency of an mRNA transcript, the method comprising steps of:

(i) obtaining an mRNA transcript comprising a coding sequence that encodes a peptide or a protein and a 3-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides, wherein the 3-terminal nucleotide of the mRNA transcript is an A nucleotide; and

(ii) delivering the mRNA transcript to cells under conditions such that the peptide or protein encoded by the coding sequence is expressed in the cells, wherein expression efficiency of the coding sequence and thereby amount of the peptide or protein encoded by the coding sequence is increased as compared to that of the coding sequence of an mRNA transcript without a 3′-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2023
From: SAHIN, UGUR; HOLTKAMP, SILKE; TÜRECI, ÖZLEM; KREITER, SEBASTIAN
To: JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Reel/Frame 064034/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2023
From: JOHANNES GUTENBERG-UNIVERSITAT MAINZ
To: BIONTECH AG
Reel/Frame 064034/0235 →
CHANGE OF NAME Recorded Jun 22, 2023
From: BIONTECH AG
To: BIONTECH SE
Reel/Frame 064072/0440 →
Priority Claims (1)
DE 10 2005 046 490.4 · Sep 28, 2005 · national
Continuity (4)
Division 16143520 · Sep 27, 2018
Continuation 15217555 · Jul 22, 2016
Division 11992638
Related Publication 20230193296A1 · Jun 22, 2023
References Cited (296)
US 4897355A · Eppstein et al. · 1990 [cited by applicant]
US 5264618A · Felgner et al. · 1993 [cited by applicant]
US 5703055A · Felgner et al. · 1997 [cited by applicant]
US 6251399B1 · Diamond et al. · 2001 [cited by applicant]
US 6472176B2 · Kovesdi et al. · 2002 [cited by applicant]
US 6500641B1 · Chen et al. · 2002 [cited by applicant]
US 6586410B1 · Wheeler et al. · 2003 [cited by applicant]
US 7303881B2 · Huang et al. · 2007 [cited by applicant]
US 7399753B2 · Mitchell et al. · 2008 [cited by applicant]
US 7462354B2 · Sette et al. · 2008 [cited by applicant]
US 7790696B2 · Gregoriadis · 2010 [cited by applicant]
US 8140270B2 · Kingsmore et al. · 2012 [cited by applicant]
US 8217016B2 · Hoerr · 2012 [cited by examiner]
US 8349558B2 · Fatho et al. · 2013 [cited by applicant]
US 8691966B2 · Kariko et al. · 2014 [cited by applicant]
US 8703142B2 · Diamond et al. · 2014 [cited by applicant]
US 8853283B2 · Platscher et al. · 2014 [cited by applicant]
US 8877206B2 · Chen et al. · 2014 [cited by applicant]
US 9115402B2 · Hacohen et al. · 2015 [cited by applicant]
US 9476055B2 · Sahin et al. · 2016 [cited by applicant]
US 10106800B2 · Sahin et al. · 2018 [cited by applicant]
US 11135312B2 · Von Der Mülbe et al. · 2021 [cited by applicant]
US 11421038B2 · Hoerr et al. · 2022 [cited by applicant]
US 11779659B2 · Sahin et al. · 2023 [cited by applicant]
US 20020025939A1 · Iversen · 2002 [cited by examiner]
US 20030083272A1 · Wiederholt et al. · 2003 [cited by applicant]
US 20030157113A1 · Terman · 2003 [cited by examiner]
US 20040132181A1 · Mitchell · 2004 [cited by examiner]
US 20040209274A2 · Daly · 2004 [cited by applicant]
US 20040235175A1 · Gaudernack · 2004 [cited by examiner]
US 20050032730A1 · Von Der Mulbe · 2005 [cited by examiner]
US 20070025968A1 · Van Der Burg et al. · 2007 [cited by applicant]
US 20090055944A1 · Korman et al. · 2009 [cited by applicant]
US 20090093433A1 · Woolf et al. · 2009 [cited by applicant]
US 20090217401A1 · Korman et al. · 2009 [cited by applicant]
US 20100129877A1 · Sahin et al. · 2010 [cited by applicant]
US 20110143397A1 · Kariko et al. · 2011 [cited by applicant]
US 20120237975A1 · Schrum et al. · 2012 [cited by applicant]
US 20130115272A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130123481A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130156849A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130203115A1 · Schrum et al. · 2013 [cited by applicant]
US 20130237593A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130237594A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130244278A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130244279A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130245106A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130245107A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130255281A1 · Bray · 2013 [cited by applicant]
US 20130266640A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130274129A1 · Katzen et al. · 2013 [cited by applicant]
US 20140010861A1 · Bancel et al. · 2014 [cited by applicant]
US 20140147454A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20150017211A1 · de Fougerolles et al. · 2015 [cited by applicant]
US 20150030576A1 · Bancel · 2015 [cited by applicant]
US 20150167017A1 · Roy et al. · 2015 [cited by applicant]
US 20170009244A1 · Sahin et al. · 2017 [cited by applicant]
EP 0726319A2 · 1996 [cited by applicant]
EP 0839912A1 · 1998 [cited by applicant]
EP 1242108A1 · 2002 [cited by applicant]
EP 1361277A1 · 2003 [cited by applicant]
EP 2569633A2 · 2013 [cited by applicant]
EP 3230458A1 · 2017 [cited by applicant]
EP 3167059B1 · 2019 [cited by applicant]
WO WO1994023031A1 · 1994 [cited by applicant]
WO WO1998014464A1 · 1998 [cited by applicant]
WO WO199914346A2 · 1999 [cited by applicant]
WO WO1999020766A2 · 1999 [cited by applicant]
WO WO1999024566A1 · 1999 [cited by applicant]
WO WO1999052503A2 · 1999 [cited by applicant]
WO WO200020029A1 · 2000 [cited by applicant]
WO WO2000067761A1 · 2000 [cited by applicant]
WO WO2001047959A2 · 2001 [cited by applicant]
WO WO2001093902A2 · 2001 [cited by applicant]
WO WO2002048377A2 · 2002 [cited by applicant]
WO WO2002083714A2 · 2002 [cited by applicant]
WO WO02098443A2 · 2002 [cited by examiner]
WO WO2003051401A2 · 2003 [cited by applicant]
WO WO2003068257A1 · 2003 [cited by applicant]
WO WO2003106692A2 · 2003 [cited by applicant]
WO WO2004004743A1 · 2004 [cited by applicant]
WO WO2005030250A2 · 2005 [cited by applicant]
WO WO2005039533A1 · 2005 [cited by applicant]
WO WO2005040816A1 · 2005 [cited by applicant]
WO WO2005075644A2 · 2005 [cited by examiner]
WO WO2005110338A2 · 2005 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2007024708A2 · 2007 [cited by applicant]
WO WO2007025760A2 · 2007 [cited by applicant]
WO WO2007031222A2 · 2007 [cited by applicant]
WO WO2007101227A2 · 2007 [cited by applicant]
WO WO2008080468A1 · 2008 [cited by applicant]
WO WO2008083174A2 · 2008 [cited by applicant]
WO WO2008085562A2 · 2008 [cited by applicant]
WO WO2008116078A2 · 2008 [cited by applicant]
WO WO2008156712A1 · 2008 [cited by applicant]
WO WO2009053041A2 · 2009 [cited by applicant]
WO WO2009118296A2 · 2009 [cited by applicant]
WO WO2009129227A1 · 2009 [cited by applicant]
WO WO2010066418A1 · 2010 [cited by applicant]
WO WO2011012316A2 · 2011 [cited by applicant]
WO WO2011143656A2 · 2011 [cited by applicant]
WO WO2012019168A2 · 2012 [cited by applicant]
WO WO2012045075A1 · 2012 [cited by applicant]
WO WO2012045082A2 · 2012 [cited by applicant]
WO WO2012135805A2 · 2012 [cited by applicant]
WO WO2012159729A1 · 2012 [cited by applicant]
WO WO2013040142A2 · 2013 [cited by applicant]
WO WO2013052523A1 · 2013 [cited by applicant]
WO WO2013090648A1 · 2013 [cited by applicant]
WO WO2013120628A1 · 2013 [cited by applicant]
WO WO2013124701A2 · 2013 [cited by applicant]
WO WO2013151663A1 · 2013 [cited by applicant]
WO WO2013151664A1 · 2013 [cited by applicant]
WO WO2013151665A2 · 2013 [cited by applicant]
WO WO2013151672A2 · 2013 [cited by applicant]
WO WO2014012051A1 · 2014 [cited by applicant]
WO WO2014071219A1 · 2014 [cited by applicant]
WO WO2014093924A1 · 2014 [cited by applicant]
WO WO2014144039A1 · 2014 [cited by applicant]
WO WO2014144711A1 · 2014 [cited by applicant]
WO WO2014144767A1 · 2014 [cited by applicant]
WO WO2014152027A1 · 2014 [cited by applicant]
WO WO2014152030A1 · 2014 [cited by applicant]
WO WO2014152031A1 · 2014 [cited by applicant]
WO WO2014152211A1 · 2014 [cited by applicant]
WO WO2014159813A1 · 2014 [cited by applicant]
WO WO2014160243A1 · 2014 [cited by applicant]
WO WO2014164253A1 · 2014 [cited by applicant]
WO WO2014168874A2 · 2014 [cited by applicant]
WO WO2015014375A1 · 2015 [cited by applicant]
WO WO2015034925A1 · 2015 [cited by applicant]
WO WO2015034928A1 · 2015 [cited by applicant]
WO WO2015038892A1 · 2015 [cited by applicant]
WO WO2015043613A1 · 2015 [cited by applicant]
WO WO2015051169A2 · 2015 [cited by applicant]
WO WO2015051173A2 · 2015 [cited by applicant]
WO WO2015058780A1 · 2015 [cited by applicant]
WO WO2015085318A2 · 2015 [cited by applicant]
WO WO2015089511A2 · 2015 [cited by applicant]
WO WO2015117620A1 · 2015 [cited by applicant]
WO WO2015164674A1 · 2015 [cited by applicant]
WO WO2015172843A1 · 2015 [cited by applicant]
WO WO2016005004A1 · 2016 [cited by applicant]
WO WO2016005324A1 · 2016 [cited by applicant]
WO WO2016062323A1 · 2016 [cited by applicant]
WO WO2016091391A1 · 2016 [cited by applicant]
WO WO2016107877A1 · 2016 [cited by applicant]
WO WO2016155809A1 · 2016 [cited by applicant]
Elango et al in “Optimized transfection of mRNA transcribed from a d(A/T) 100 tail-containing vector” (Biochem. Biphys. Comm. vol. 330, pp. 958-966, published Mar. 19, 2005). (Year: 2005). [cited by examiner]
Malone et al in “Cationic liposome-mediated RNA transfection” (PNAS 1989 vol. 86, pp. 6077-6081). (Year: 1989). [cited by examiner]
Hess et al in (Cancer Immunol Immunother (2006 vol. 55: pp. 672-683, published online Aug. 2, 2005). (Year: 2005). [cited by examiner]
Caruso et al (published online Feb. 3, 2005): (Year: 2005). [cited by examiner]
Hunziker et al (Virology 2004 vol. 330, pp. 196-208). (Year: 2004). [cited by examiner]
Heiser et al in “Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.” (J. Immunol. 2000, vol. 164, pp. 5508-5514; IDS ref). (Year: 2000). [cited by examiner]
Heiser et al in “Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors” J. Clin. Invest. 2002, vol. 109, pp. 409-417; IDS ref). (Year: 2002). [cited by examiner]
Xue et al (Infection And Immunity, Nov. 2004, pp. 6324-6329): (Year: 2004). [cited by examiner]
Lingna Wang Dissertation U of Texas Aug. 2005 (Year: 2005). [cited by examiner]
Castagnetti & Ephrussi in “Orb and a long poly(A) tail are required for efficient oskar translation at the posterior pole of the [cited by applicant]
Passmore et al (Nature Reviews vol. 23, 2022; pp. 93-106) (Year: 2021). [cited by applicant]
Agrawal et al., Trend in Biotechnology, 14(10): 376-387, 1996. [cited by applicant]
Bargmann, C.I., Hung, M.C., and Weinberg, R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226-230 (1986). [cited by applicant]
Beckel-Mitchener, A. C., et al., Poly(A) tail length-dependent stabilization of GAP-43 mRNA by the RNA-binding protein HuD, Journal of Biological Chemistry, 277(31):27996-28002, (2002). [cited by applicant]
Bei et al.J Immunother. May 1998;21(3):159-69. [cited by applicant]
Boczkowski et al. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J Exp. Med. 184: 465-472. [cited by applicant]
Boczkowski, D., Nair, S.K., Nam, J.H., Lyerly H.K., and Gilboa, E. (2000). Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells… [cited by applicant]
Bowerman, NA. “Engineering the binding properties of the T cell receptor: peptide: MHC ternary complex that governs T cell activity.” Mol. Immun. 46: 3000-3008, 2009. [cited by applicant]
Brickner et al. J Exp. Med 193(2) 195-205 (2001). [cited by applicant]
Carralot, J.P., Probst, J., Hoerr, I., Scheel, B., Teufel, R., Jung, G., Rammensee, H.G., and Pascolo, S. (2004). Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol… [cited by applicant]
Carrazana E. J., et al., The vasopressin mRNA poly(A) tract is unusually long and increases during stimulation of vasopressin gene expression in vivo, Mol & Cell Biol, 8(6):2267-2274, (1988). [cited by applicant]
Cloning vector pGL3 Promoter, downloaded Jan. 16, 2021, 3 pages. [cited by applicant]
Condon, C., Watkins, S.C., Celluzzi, C.M., Thompson, K., and Falo, L.D., Jr. (1996). DNA-based immunization by in vivo transfections of dendritic cells. Nat. Med. 2, 1122-1128. [cited by applicant]
Conry et al. (1995). Characterization of a messenger RNA polynucleotide vaccine vector, Cancer Res. 55: 1397-1400. [cited by applicant]
Conry, R.M., LoBuglio, A.F., Kantor, J., Schlom, J., Loechel, F., Moore, S.E., Sumerel, L.A., Barlow, D.L., Abrams, S., and Curiel, D.T. (1994). Immune response to a carcinoembryonic antigen polynucleotide vaccine. Canc… [cited by applicant]
Conry, R.M., LoBuglio, A.F., Loechel, F., Moore, S.E., Sumerel, L.A., Barlow, D.L., and Curiel, D.T. (1995a). A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 2, 59-65. [cited by applicant]
Conry, R.M., LoBuglio, A.F., Wright, M., Sumerel, L., Pike, M.J., Johanning, F., Benjamin, R., Lu, D., and Curiel, D.T. (1995b). Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55, 1397-14… [cited by applicant]
Coulie et al. (1995). A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. USA 92: 7976-7980. [cited by applicant]
Cox, G.J., Zamb, T.J., and Babiuk, L.A. (1993). Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67, 5664-5667. [cited by applicant]
Davis, H.L., Michel, M.L., and Whalen, R.G. (1993). DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2, 1847-1851. [cited by applicant]
Del Val et al., Cell, vol. 66, Issue 6, Sep. 20, 1991, pp. 1145-1153. [cited by applicant]
Dengjel, J et al. Glycan side chains on naturally presented MHC class II ligands J Mass Spectrom, 2005. [cited by applicant]
Ding et al. Genome remodeling in a basal-like breast cancer metastasis and xenograft Nature, 464: 999-1005, 2010. [cited by applicant]
Dolgin, “The Billion-Dollar Biotech,” Nature, vol. 522, pp. 26-28, Jun. 4, 2015. [cited by applicant]
Edmonds, “Progress in Nucleic Acid Research and Molecular Biology”, (2002), vol. 71, p. 285-389. [cited by applicant]
Elango, N. et al., Optimized transfection of mRNA transcribed from a d(A/T) 100 tail-containing vector, Biochem Biophys Res Commun., 330(3):958-66 (2005). [cited by applicant]
Fritsch, E. F. et al. HLA-Binding Properties of Tumor Neoepitopes in Humans Cancer Immunology Research, 2: 522-529, 2014. [cited by applicant]
Gallie et al. Mol Gen Genet (1991) 228:258-264. [cited by applicant]
Gallie, “A tale of two termini: A functional interaction between termini of an mRNA is a prerequisite for efficient translation initiation”, Gene, Elsevier 1-11 (1998). [cited by applicant]
Gallie, D.R. (1991). The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 5, 2108-2116. [cited by applicant]
Gilkeson, G.S., Pippen, A.M., and Pisetsky, D.S. (1995). Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J. Clin. Invest. 95, 1398-1402. [cited by applicant]
Gnirke, A. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing Nat. Biotechnol, 2009. [cited by applicant]
Goya, R. et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors, Bioinformatics Bioinformatics, 26: 730-736, 2010. [cited by applicant]
Greenblatt, M.S., Bennett, W.P., Hollstein, M., and Harris, C.C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878. [cited by applicant]
Gryaznov et al., Biochim. Biophys. Acta, 1489: 131-140, 1999. [cited by applicant]
Guhaniyogi et al., “Regulation of mRNA stability in mammalian cells”, Gene, Elsevier, 11-23 (2001). [cited by applicant]
Guyre et al., Cancer Immunother (1997) 45:146-148. [cited by applicant]
Hacohen Decl. dated Feb. 16, 2014 filed in U.S. Appl. No. 13/108,610, 10 pages. [cited by applicant]
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M.A., Lallas, C.D., Dahm, P., Niedzwiecki, D., Gilboa, E., and Vieweg, J. (2002). Autologous dendritic cells transfected with prostate-specific antigen RNA stim… [cited by applicant]
Heiser, A., Dahm, P., Yancey, D.R., Maurice, M.A., Boczkowski, D., Nair, S.K., Gilboa, E., and Vieweg, J. (2000). Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific… [cited by applicant]
Hoerr, I., Obst, R., Rammensee, H.G., and Jung, G. (2000). In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30, 1-7. [cited by applicant]
Holtkamp et al., Gene Therapy: prepublished online as Blood First Edition Paper, pp. 3009-4017, (2006). [cited by applicant]
Holtkamp, Silke, et al., “Modification of Antigen-Encoding RNA Increases Stability, Translational Efficacy, and T-Cell Stimulatory Capacity of Dendritic Cells,” Blood, vol. 108, No. 13. (2006). [cited by applicant]
International Preliminary Report on Patentability Chapter I, Dated Apr. 1, 2008, Filed in relation to PCT Application No. PCT/EP2006/009448, Filed Apr. 5, 2007, Entitled “Modification of RNA, Producing an Increased Tran… [cited by applicant]
International Search Report (ISR), Dated May 8, 2007, Filed in relation to PCT Application No. PCT/EP2006/009448, Filed Apr. 5, 2007, Entitled “Modification of RNA, Producing an Increased Transcript Stability and Transl… [cited by applicant]
Johanning et al. Nucleic Acids Res. May 11, 1995; 23(9): 1495-1501. [cited by applicant]
Kenter, G. G. et al. “Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 sequences of High-risk human papillomavirus 16 in End-stage cervical cancer patients shows low toxicity and robust immunoge… [cited by applicant]
Keogh, E. et al. “Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity” J. Immunol. 167: 787-796, 2001. [cited by applicant]
Krieg & Melton, vol. 12 No. 18 (1984) Nucleic Acids Research. [cited by applicant]
Lemmel, Claudia et al., Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling Nat Biotechnol, 2004. [cited by applicant]
Lennerz et al. (2005). The response of autologous T cells to a human melanoma is dominated by mutated neoantigens, Proc. Natl. Acad. Sci. USA 102: 16013-16018. [cited by applicant]
Ley et al. (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome, Nature 456: 66-72. [cited by applicant]
Li et al., Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccine, Cancer 2011, 3, 4191-4211. [cited by applicant]
Li, X., et al., “Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter,” Journal of Biological Chemistry, 273(52):34970-34975 (1998). [cited by applicant]
Maksyutov and Zagrebelnaya (1993). ADEPT: a computer program for prediction of protein antigenic determinants, Comput. Appl. Biosci. 9: 291-297. [cited by applicant]
Malone, R.W., Felgner, P.L., and Verma, I.M. (1989). Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. USA 86, 6077-6081. [cited by applicant]
Mandelboim et al. (1995). Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides, Nature Medicine 1: 1179-1183. [cited by applicant]
Mardis, ER., Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome, New England J. Med., 361:1058-1066 (2009). [cited by applicant]
Margulies, Marcel et al., Genome Sequencing in Open Microfabricated High Density Picoliter Reactors Nature, 2005. [cited by applicant]
Martinon et al. (1993). Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol 23, 1719-1722. [cited by applicant]
Mayer et al., Anticancer Research 25:3917-3924 (2005). [cited by applicant]
Meyerson, M. et al. Advances in understanding cancer genomes through second-generation sequencing Nature Rev. Genetics. 11:685-695, 2010. [cited by applicant]
Mignone, F., et al., “Untranslated Regions of mRNAs,” Genome Biology, vol. 3, No. 3. (2002). [cited by applicant]
Monach et al. (1995). A unique tumor antigen produced by a single amino acid substitution, Immunity 2: 45-59. [cited by applicant]
Mortazavi (2008). Mapping and quantifying mammalian transcriptomes by RNA-Seq, Nature Methods 5: 621-628. [cited by applicant]
Parker et al., J. Immunol. 152 (1994), 163-175. [cited by applicant]
Parkhurst, MR. et al. “Improved Induction of Melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.” J. Immunol. 157: 2549-2548, 1996. [cited by applicant]
Parmiani, G. et al. “Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials.” The Journal of Immunology, 178: 1975-1979, 2007. [cited by applicant]
PBluescript II KS Sequence and Map, downloaded Jan. 16, 2021, 11 pages. [cited by applicant]
Peak, I. and Axel, R., Glucocorticoids enhance stability of human growth hormone mRNA, Mol & Cell Biol., 7(4):1496-1507, (1987). [cited by applicant]
Perissi et al., Electron Spin Resonance and Differential Scanning Calorimetry as Combined Tools for the Study of Liposomes in the Presence of Long Chain Nitroxides, 106 J_ of Phys. Chem. B 10468 (2002). [cited by applicant]
Pesole, G., et al., “Structural and Functional Features of Eukaryotic mRNA Untranslated Regions,” Gene: An International Journal on Genes and Genomes, vol. 276, No. 1-2, (2001). [cited by applicant]
Pfohl et al., Biological Polyelectrolyte Complexes in Solution and Confined on Patterned Surfaces, 198-200 Colloids & Surfaces A: Physicochemical and Eng. Aspects 613 (2002). [cited by applicant]
PGL3 Luciferase Reporter Vectors, downloaded Jan. 16, 2021, 3 pages. [cited by applicant]
Pilla, L. et al. Multipeptide vaccination in cancer patients Expert Opinion on Biological Therapy, 9: 1043-1055, 2009. [cited by applicant]
Pleasance, E. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature, 463: 184-190, 2010. [cited by applicant]
Pleasance, E. et al., A comprehensive catalogue of somatic mutations from a human cancer genome, Nature, 463:191-196 (2010). [cited by applicant]
Preiss, T. and Hentze, M.W. (1998). Dual function of the messenger RNA cap structure in poly(A)-tail promoted translation in yeast. Nature 392, 516-520. [cited by applicant]
Proudfoot, Nicholas J., Cell, vol. 10, 559-570. Apr. 1977. [cited by applicant]
Rabinovich, P. et al., Synthetic Messenger RNA as a Tool for Gene Therapy, Human Gene Therapy, 17:1027-1-35 (2006). [cited by applicant]
Rammansee 2008, Chapter 50: Cancer Vaccines: Some Basic Considerations, Genomic and Personalized Medicine, Hungtington and Ginsburg. E-published on Nov. 11, 2008. [cited by applicant]
Rammensee (2006). “Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer,” Immunol Cell Biol. 84(3):290-4. [cited by applicant]
Rammensee et al. (2002). “Toward patient-specific tumor antigen selection for vaccination,” Immunol. Rev. 188: 164-176. [cited by applicant]
Rammensee et al., Immunogenentics, 50 (1999), 213-219. [cited by applicant]
Rao (1994). “Epitope-based vaccines: One step at a time,” Proc. Indian natn. Sci. Acad. B60: 419-424. [cited by applicant]
Ressing, M. et al. “Human CTL epitopes encoded by human papillomavirus types 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides” J. Immunol. 154:5934-5943, 1995. [cited by applicant]
Richter Joel D: “Cytoplasmic polyadenylation in development and beyond”, Jun. 1999, Microbiology and Molecular Biology Reviews, vol. 63, NR. 2, pp. 446-456, XP002641650. [cited by applicant]
Russell and Liebhaber in “The stability of human beta-globin mRNA is dependent on structural determinants positioned within its 3′ untranslated region”(Blood Journal: 1996, vol. 87: pp. 5314-5323). [cited by applicant]
Russell, J. and Liebhaber, S., The stability of human beta-globin mRNA is dependent on structural determinants positioned within its 3′ untranslated region, Blood, 87(12):5314-23 (1996). [cited by applicant]
Saenz-Badillos et al. (2001). RNA as a tumor vaccine: a review of the literature, Exp Dermatol. 10(3):143-54. [cited by applicant]
Segal et al. (2008). Epitope landscape in breast and colorectal cancer, Cancer Res. 68: 889-892. [cited by applicant]
Sensi and Aanichini, Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T cell-mediated Patient-Specific Immunotherapy, Clin. Cancer Res. 2006:12(17), 5023. [cited by applicant]
Sette, A. et al. “Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays” Mol. Immunol. 31: 813-822, 1994. [cited by applicant]
Sette, A. et al. “The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T cell Epitopes.” J. Immunol. 153: 5586-5592, 1994. [cited by applicant]
Shah et al. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary, N. Eng. J Med. 360: 2719-2729. [cited by applicant]
Sjoblom et al. (2006). The consensus coding sequences of human breast and colorectal cancers, Science 314: 268-274. [cited by applicant]
Spooner, R.A., Deonarain, M.P., and Epenetos, A.A. (1995). DNA vaccination for cancer treatment. Gene Ther. 2, 173-180. [cited by applicant]
Stephens et al. (2005). “A screen of the complete protein kinase gene family identities diverse patterns of somatic mutations in human breast cancer,” Nature Genetics, 37: 590-592. [cited by applicant]
Strong, T.V., Hampton, T.A., Louro, I., Bilbao, G., Conry, R.M., and Curiel, D.T. (1997). Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression. G… [cited by applicant]
Su, Z., Dannull, J., Heiser, A., Yancey, D., Pruitt, S., Madden, J., Coleman, D., Niedzwiecki, D., Gilboa, E., and Vieweg, J. (2003). Immunological and clinical responses in metastatic renal cancer patients vaccinated w… [cited by applicant]
Tang, D.C., DeVit, M., and Johnston, S.A. (1992). Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154. [cited by applicant]
Tanguay et al., “Translational efficiency is regulated by the length of the 3′ untranslated region”, Molecular and Cellular Biology, American Society for Microbiology, 146-156 (1996). [cited by applicant]
Teufel, R., Carralot, J.P., Scheel, B., Probst, J., Walter, S., Jung, G., Hoerr, I., Rammensee, H.G., and Pascolo, S. (2005). Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-spe… [cited by applicant]
ThermoFisher Esp3l (BsmBI) datasheet, downloaded Jan. 16, 2021, 4 pages. [cited by applicant]
Thomson et al., J Virology (1998), 72(3):2246-2252. [cited by applicant]
Toes et al. (1997). Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string- of-beads fashion, Proc. Natl. Acad.… [cited by applicant]
Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Feigner, P.L., Dwarki, V.J., Gromskowski, S.H., Deck, R.R., DeWitt, C.M., Friedman, A., et al. (1993). Heterologous protection against influenza by injection of D… [cited by applicant]
UniProtKB—P36888 (FLT3_HUMAN), last sequence update: Aug. 21, 2007. [cited by applicant]
UniProtKB—Q5SW79 (CE170_HUMAN), last sequence update: Dec. 21, 2004. [cited by applicant]
UniProtKB—Q9NVD7 (Parva_Human), last sequence update: Oct. 1, 2000. [cited by applicant]
UniProtKB, “Print-outs from the UniProtKB database concerning the CEP170, Parva and FLT3 genes.” [cited by applicant]
Van der Bruggen et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science 254: 1643-1647. [cited by applicant]
Van Laere AS, Nguyen M, Braunschweig M. et al. A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig. Nature. 2003;425(6960):832-836. [cited by applicant]
Vioque, et al. J. Mol. Biol., (1988), vol. 202, p. 835-848. [cited by applicant]
Wang, B., Merva, M., Dang, K., Ugen, K.E., Williams, W.V., and Weiner, D.B. (1995). Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Hum. Gene Ther. 6, 407-418. [cited by applicant]
Wang, B., Ugen, K.E., Srikantan, V., Agadjanyan, M.G., Dang, K., Refaeli, Y., Sato, A.I., Boyer, J., Williams, W.V., and Weiner, D.B. (1993). Gene inoculation generates immune responses against human immunodeficiency vi… [cited by applicant]
Weinschenk et al. (2002), Integrated functional genomics approach for the design of patient-individual antitumor vaccines, Cancer Res 62: 5818-5827. [cited by applicant]
Wickens M et al: “A PUF family portrait: 3'UTR regulation as a way of life”, Trends in Genetics, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 18, nr. 3, Mar. 1, 2002, pp. 150-157, XP004340609. [cited by applicant]
Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., and Feigner, P.L. (1990). Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468. [cited by applicant]
Wood et al. (2007). The genomic landscapes of human breast and colorectal cancers, Science 318: 1108-1113. [cited by applicant]
Wortzel et al. (1983). Multiple tumour-specific antigens expressed on a single tumour cell, Nature 304: 165-167. [cited by applicant]
Written Opinion of the International Search Authority, Dated May 8, 2007, Filed in relation to PCT Application No. PCT/EP2006/009448, Filed Apr. 5, 2007, Entitled “Modification of Rna, Producing an Increased Transcript … [cited by applicant]
Ying, H., Zaks, T.Z., Wang, R.F., Irvine, K.R., Kammula, U.S., Marincola, F.M., Leitner, W.W., and Restifo, N.P. (1999). Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 5, 823-827. [cited by applicant]
Yu. Jia, et al., Structural and Functional Analysis of an mRNP Complex that Mediates the High Stability of Human Beta-globulin mRNA, Molecular and Cellular Biology, Vo. 21, No. 17. (2001). [cited by applicant]
Zhou et al., Hum. Gene Ther., 10(16):2719-24, 1999. [cited by applicant]
Sachs, A., The role of poly(A) in the translation and stability of mRNA, Curr Opin Cell Biol., 2(6):1092-8 (1990). [cited by applicant]
Khanam, T. et al., Poly(A)-binding protein binds to A-rich sequences via RNA-binding domains 1+2 and 3+4, RNA Biol., 3(4):170-7 (2006). [cited by applicant]
Milone, J. et al., Characterization of deadenylation in trypanosome extracts and its inhibition by poly(A)-binding protein Pab1p, RNA, 10(3):448-57 (2004). [cited by applicant]
Chen, CY and Shyu, AB, AU-rich elements: characterization and importance in mRNA degradation, Trends Biochem Sci., 20(11):465-70 (1995). [cited by applicant]
Gallie, DR. et al., The histone 3′-terminal stem-loop is necessary for translation in Chinese hamster ovary cells, Nucleic Acids Res., 24(10):1954-62 (1996). [cited by applicant]
Zhao, Y. et al., Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res., 70(22):9053-61 (2010). [cited by applicant]
Pandey, NB and Marzluff, WF, The stem-loop structure at the 3′ end of histone mRNA is necessary and sufficient for regulation of histone mRNA stability, Mol Cell Biol., 7(12):4557-9 (1987). [cited by applicant]
Bernstein, P. et al., The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro, Mol Cell Biol., 9(2):659-70 (1989). [cited by applicant]
Trepotec, Z. et al., Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life, RNA, 25(4):507-518 (2019). [cited by applicant]
Leppek, K. et al., Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics, Nat Commun., 13(1):1536 (2022). [cited by applicant]
Dubensky, TW, Jr. et al., Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer, J Virol., 70(1):508-19 (1996). [cited by applicant]
Tarun, S. et al., Deardorff JA, Sachs AB. Translation initiation factor elF4G mediates in vitro poly(A) tail-dependent translation, Proc Natl Acad Sci USA, 94(17):9046-51 (1997). [cited by applicant]